Skip to content Skip to footer
Subscribe Now
NEWS

DeepCyte Secures $1.5M to Advance AI-Driven Single-Cell Toxicology in Drug Development

Shots: DeepCyte, a techbio startup focused on advancing AI-powered toxicology for drug development, has officially launched with $1.5 million in seed funding, introducing two solutions to help biopharma teams detect, predict, and understand drug toxicity in human cells at single-cell resolution DeepCyte's MetaCore, a high-throughput single-cell metabolomics platform, leverages laser-based sampling and mass spectrometry to…
9 hours ago

Read more

MAGAZINE

PharmaShots Magazine-April-2026 Edition

Shots: AI is redefining compliance from reactive to predictive, as this April edition highlights how AI-powered systems are transforming regulatory oversight into a continuous, real-time, and data-driven function, enabling early risk detection, automated audits, and smarter regulatory collaboration across the pharma value chain. Strategic dealmaking and AI partnerships shape industry momentum, with March witnessing high-value…
11 hours ago

Read more

INSIGHTS+

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026 

Headlines, Trends, and the Signals Shaping the Future of Biopharma  A Quarter That Reset the Biopharma Narrative  The first quarter of 2026 did not simply continue the momentum of the global biopharmaceutical industry; it redefined its direction.  From multi-billion-dollar acquisitions and accelerating rare disease breakthroughs to AI-powered discovery collaborations and gene therapy approvals, the industry demonstrated a clear shift toward precision innovation, strategic consolidation, and next-generation…
April 1, 2026

Read more

VIEWPOINTS

Reimagining Migraine Treatment: Alon Ironi of Theranica on Nerivio’s Journey to Nationwide Coverage 

Shots:  What started as a father’s determination to find a better solution has grown into a widely reimbursed therapy. Along the way, strong clinical evidence, early physician support, and carefully designed payer pilots helped unlock nationwide coverage, reaching nearly 130 million lives across Blue Cross Blue Shield plans.  In this conversation, Alon explains how Nerivio’s dual acute and preventive…
March 23, 2026

Read more

VIEWPOINTS

From Denials to Decisions: Dr. Wael Khouli of Authsnap on AI-Powered Healthcare Appeals 

Shots:  Did you know that nearly 15–20% of healthcare claims in the U.S. are denied on first submission, creating billions of dollars in administrative costs and forcing providers into complex, time-consuming appeals processes that strain revenue cycles, clinical staff, and patient care continuity?    Authsnap is an AI healthcare technology company helps providers manage insurance denials and…
March 16, 2026

Read more

MAGAZINE

PharmaShots Magazine-March-2026 Edition

Shots AI is transforming clinical trial oversight from periodic monitoring to continuous, real-time intelligence, enabling early detection of safety signals, protocol deviations, and operational risks while strengthening data integrity and patient protection. Advanced analytics and machine learning are powering predictive, risk-based monitoring, integrating data from decentralized trials, wearables, ePROs, and multiple clinical systems to prioritize…
March 12, 2026

Read more

EVENTS

ISPE Singapore Conference & Exhibition 2026 | August 19-21 | Suntec Singapore

The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical manufacturing professionals. The annual meeting highlights best practices and services – from manufacturing facility design to finished product. Whether joining onsite in Singapore or on-demand, this is your opportunity to gather the latest updates and…
March 11, 2026

Read more

VIEWPOINTS

Bridging Innovation and Clinical Reality: Shalabh Gupta, CEO of Unicycive Therapeutics, on the Future of Biotech

Shots  Cross-industry lessons from technology, design thinking, and startups can reshape drug development by encouraging faster iteration, disciplined decision-making, and a stronger focus on real patient needs, unlocking innovations that traditional biotech models may overlook.    Clinical experience and thoughtful engagement with the U.S. Food and Drug Administration highlight the importance of patient insights, transparent…
March 9, 2026

Read more

VIEWPOINTS

Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision 

Shots:  The EU approval of Vueway for neonates, infants, and toddlers is a milestone for pediatric imaging as it allows high-quality MRI imaging at half the GBCA dose, supporting reduced gadolinium exposure in vulnerable young patients  Vueway’s gadopiclenol demonstrates safety and diagnostic performance by offering high stability, low dissociation risk, and 2.5–4× greater relaxivity than other macrocyclic GBCAs, enabling effective imaging…
March 2, 2026

Read more

TOP 20

Top 20 Radiopharmaceutical Companies of 2026

Shots:  The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.  Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
February 27, 2026

Read more

Load more